Loading...
NYSE: BMY
Bristol-Myers Squibb Company
Healthcare · Drug Manufacturers - General
●S&P 500 since 1957
Market Cap
$119.59B
52w High
$62.89
52w Low
$42.52
P/E
16.99
Volume
3.70M
Outstanding Shares
2.04B
Valuation Data Insufficient
The DCF model's fair value estimate is more than 3× the current stock price. This typically indicates unreliable model inputs — such as irregular cash flows or balance sheet distortions — rather than a genuine opportunity, so the valuation is not shown.
Company profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide.
CEOChristopher S. Boerner
SectorHealthcare
IndustryDrug Manufacturers - General
Employees34,100
IPO dateJun 1, 1972
Valuation
Forward P/E—
EV/EBITDA10.11
Enterprise value$147.02B
Stock splits
Aug 7, 20011000000:951777
Mar 1, 19992:1
Mar 3, 19972:1
Jun 10, 19872:1
May 27, 19832:1
May 31, 19772:1
Profitability & growth
Revenue growth1.3%
Gross margin67.65%▲19.11%vs FY2024
Operating margin26.34%▲31.74%vs FY2024
ROE38.18%▲169.70%vs FY2024
Analyst consensus
RatingHold
Target price$62.73▲6.82%
19
Buy
20
Hold
2
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Apr 23, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
$1.46
$1.09
Q3FY25
ActualEst.
$1.63
$1.52
Q4FY25
ActualEst.
$1.26
$1.23
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$12.27B
$11.44B
Q3FY25
ActualEst.
$12.22B
$11.85B
Q4FY25
ActualEst.
$12.5B
$12.28B
Q1FY26
Next Est.
—